Genomic Directed Salvage Chemotherapy With Either Liposomal Doxorubicin Or Topotecan
Status:
Terminated
Trial end date:
2009-10-01
Target enrollment:
Participant gender:
Summary
This pilot study will help us to determine the success of using a special technique called
microarray technology to examine cancer genes in order to predict how individual women will
respond to one of two therapies, liposomal doxorubicin or topotecan, and which will be more
effective in treating ovarian cancer that has returned (recurrent ovarian cancer). We believe
that this study may lead to a means by which microarray technology can predict the most
effective treatment decision, based on the genetic characteristics of her tumor tissue, for a
woman with recurrent ovarian cancer.
Another purpose of this study is to determine how quickly a woman with recurrent ovarian
cancer will respond to treatment (treatment response rate) and to evaluate the accuracy of
the genomic predictions.
Recent data suggest that microarray technology can predict a patient's response to
chemotherapy; this has not yet been proven in a forward-looking study which is why we are
conducting this research.
Phase:
N/A
Details
Lead Sponsor:
H. Lee Moffitt Cancer Center and Research Institute